Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;103(3):317-326.
doi: 10.1111/cen.15252. Epub 2025 Apr 29.

Elevated Triglyceride-Glucose Index Is Associated With Insulin Resistance, Metabolic Syndrome Components, Nonalcoholic Fatty Liver Disease, and Adverse Pregnancy Outcomes in Chinese Women With Polycystic Ovary Syndrome

Affiliations

Elevated Triglyceride-Glucose Index Is Associated With Insulin Resistance, Metabolic Syndrome Components, Nonalcoholic Fatty Liver Disease, and Adverse Pregnancy Outcomes in Chinese Women With Polycystic Ovary Syndrome

Jiaxing Feng et al. Clin Endocrinol (Oxf). 2025 Sep.

Abstract

Aim: To investigate the associations of triglyceride-glucose index (TyG) with anthropometric characteristics, metabolic/endocrine profiles, and pregnancy outcomes in Chinese women with polycystic ovary syndrome (PCOS).

Methods: This secondary analysis of the Acupuncture and Clomiphene for Chinese Women with Polycystic Ovary Syndrome trial (PCOSAct) included 956 participants with prospectively collected data. TyG was calculated using fasting triglyceride and glucose levels (Ln [TG (mg/dL) × FPG (mg/dL)/2]). Linear regression and trend analyses evaluated relationships between TyG and clinical parameters. Receiver operating characteristic (ROC) curves assessed TyG's predictive capacity for insulin resistance (IR), metabolic syndrome (MS), and nonalcoholic fatty liver disease (NAFLD). Multivariable logistic regression estimated risks for metabolic outcomes and pregnancy outcomes.

Results: Linear trends revealed that the TyG was positively associated with age, body mass index (BMI), waist circumference, hip circumference, waist-to-hip ratio, systolic blood pressure, diastolic blood pressure, FPG, fasting insulin, the homeostatic model assessment for insulin resistance (HOMA-IR), total cholesterol, triglycerides, low-density lipoprotein (LDL), apolipoprotein B, free androgen index, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the prevalence of IR, MS, and NAFLD across various standards. Conversely, TyG was negatively correlated with the quantitative insulin sensitivity check index (QUICKI), high-density lipoprotein (HDL), apolipoprotein A1, sex hormone-binding globulin (SHBG), and the prevalence of ovulation per cycle, conception, pregnancy, and live birth. After adjusting for age and BMI, a significant linear relationship was observed between TyG and components of MS, IR markers, and ALT. The ROC curve analysis indicated that the AUCMS-IDF was 0.871 (95% CI: 0.846-0.896), with a sensitivity of 81.4% and specificity of 81.2% at a cut-off value of 8.745, and the AUCIR-HOMA-IR was 0.782 (95% CI: 0.753-0.811), with 71.9% sensitivity and 70.3% specificity at a cut-off of 8.585, and the AUCNAFLD was 0.705 (95% CI: 0.644-0.766), with 76.8% sensitivity and 59.3% specificity at a cut-off value of 8.665. Logistic regression analysis demonstrated that participants in the highest quartile (Q4) of TyG had significantly higher odds ratios (OR) for MS (OR: 38.36, 95% CI: 20.03-73.46, P-trend < 0.001) and IR (OR: 12.49, 95% CI: 7.3-21.35, P-trend < 0.001) compared to those in the lowest quartile (Q1), while NAFLD showed a marginal association (OR: 2.56, 95% CI: 1.00-6.55, P-trend = 0.069) after adjusting for confounding factors. Conversely, participants in Q1 of TyG had higher OR of conception (OR: 1.56, 95% CI: 1.04-2.35, p < 0.05), pregnancy (OR: 2.35, 95% CI: 1.46-3.79, p < 0.01), and live birth (OR: 2.32, 95% CI: 1.42-3.78, p < 0.01) compared to those in Q4 after adjusting for treatments.

Conclusions: Elevated TyG index strongly associates with adverse metabolic trajectories, and adverse pregnancy outcomes in PCOS patients. This biomarker shows particular utility for identifying metabolic dysfunction, suggesting clinical potential for risk stratification in PCOS management.

Keywords: insulin resistance; metabolic syndrome; nonalcoholic fatty liver disease; polycystic ovary syndrome; pregnancy outcomes; triglyceride‐glucose index.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The results of ROC curve analysis regarding the predictability of TyG in IR (A), MS (B) and NAFLD (C).
Figure 2
Figure 2
Logistic regression analysis of TyG quartiles and pregnancy outcomes. (A) univariate logistic regression; (B) adjusting for treatments outcomes were expressed as OR (95% CI). *p < 0.05; **p < 0.01; ***p < 0.001.

References

    1. Wekker V., van Dammen L., Koning A., et al., “Long‐Term Cardiometabolic Disease Risk in Women With PCOS: A Systematic Review and Meta‐Analysis,” Human Reproduction Update 26, no. 6 (2020): 942–960, 10.1093/humupd/dmaa029. - DOI - PMC - PubMed
    1. Chen W. and Pang Y., “Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites,” Metabolites 11, no. 12 (2021): 869, 10.3390/metabo11120869. - DOI - PMC - PubMed
    1. Revised 2003 Consensus on Diagnostic Criteria and Long‐Term Health Risks Related to Polycystic Ovary Syndrome (PCOS),” Human Reproduction 19, no. 1 (2004): 41–47, 10.1093/humrep/deh098. - DOI - PubMed
    1. DeFronzo R. A., Tobin J. D., and Andres R., “Glucose Clamp Technique: A Method for Quantifying Insulin Secretion and Resistance,” American Journal of Physiology‐Endocrinology and Metabolism 237, no. 3 (1979): E214–E223, 10.1152/ajpendo.1979.237.3.E214. - DOI - PubMed
    1. Ni R., Mo Y., Chen X., Zhong J., Liu W., and Yang D., “Low Prevalence of the Metabolic Syndrome but High Occurrence of Various Metabolic Disorders In Chinese Women With Polycystic Ovary Syndrome,” European Journal of Endocrinology 161, no. 3 (2009): 411–418, 10.1530/EJE-09-0298. - DOI - PubMed

Supplementary concepts